Flurizan’s failure adds value

Myriad Genetics Inc. and partner H. Lundbeck A/S were surely disappointed when Flurizan tarenflurbil failed a Phase III trial to treat mild Alzheimer’s disease. But investors made it very clear that they would rather the company focused its resources on its molecular diagnostics business.

Indeed, while Phase III failures usually result in stock price declines of 40-60% or more, Myriad shares rose $4.95 (10%) to $52.88 on the week.

But while institutional investors told BioCentury the company’s entire value stems from its molecular diagnostics business, Myriad said it plans to continue developing its therapeutic pipeline anyway.

Myriad has three business units: research, molecular diagnostics and drug development. The research unit is focused on discovering genes and

Read the full 1147 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE